EFEKTIVITAS PENGGUNAAN KORTIKOSTEROID TERHADAP PASIEN COVID-19 DERAJAT BERAT DENGAN ARDS: Tinjauan Sistematik

Soraya Maulidina, . (2022) EFEKTIVITAS PENGGUNAAN KORTIKOSTEROID TERHADAP PASIEN COVID-19 DERAJAT BERAT DENGAN ARDS: Tinjauan Sistematik. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.

[img] Text
ABSTRAK.pdf

Download (193kB)
[img] Text
AWAL.pdf

Download (772kB)
[img] Text
BAB 1.pdf

Download (141kB)
[img] Text
BAB 2.pdf
Restricted to Repository UPNVJ Only

Download (658kB)
[img] Text
BAB 3.pdf
Restricted to Repository UPNVJ Only

Download (222kB)
[img] Text
BAB 4.pdf
Restricted to Repository UPNVJ Only

Download (368kB)
[img] Text
BAB 5.pdf

Download (130kB)
[img] Text
DAFTAR PUSTAKA.pdf

Download (225kB)
[img] Text
RIWAYAT HIDUP.pdf
Restricted to Repository UPNVJ Only

Download (102kB)
[img] Text
LAMPIRAN.pdf
Restricted to Repository UPNVJ Only

Download (1MB)
[img] Text
HASIL PLAGIARISME.pdf
Restricted to Repository staff only

Download (13MB)
[img] Text
ARTIKEL KI.pdf
Restricted to Repository staff only

Download (324kB)

Abstract

Introduction: ARDS is a major complication of COVID-19 infection and is associated with a high mortality rate. Currently, no definitive therapy has been shown to reduce ARDS-related mortality with either COVID-19 or non-COVID-19 etiology. The mechanism COVID-19 progresses to ARDS is thought to be due to a cytokine storm. The anti-inflammatory effect of corticosteroids may reduce pulmonary and systemic hyperinflammation due to increased secretion of proinflammatory cytokines. This systematic review will review the effectiveness of using corticosteroids in severe COVID-19 patients with ARDS. Method: A systematic review was conducted by searching the literature on Pubmed and Google Scholar databases with reference to the PRISMA-P method. The literature obtained was then selected through the JBI Critical Appraisal Checklist. Results: administration of corticosteroids with low-high doses of IV methylprednisolone 0.6 – 8 mg/kg/day or high doses of IV dexamethasone 10 – 20 mg/day for 10 days during the early phase of ARDS or risk of developing ARDS (clinical worsening >7 days of onset symptoms) or >72 hours of hospitalization yielded beneficial outcomes in severe COVID-19 patients with ARDS. Corticosteroids were associated with a decreased blood CRP levels, improved ventilation and oxygenation, but did not reduced the risk of mortality and decrease the duration of hospitalization. Conclusion: the use of corticosteroids helps to provide beneficial outcomes in severe COVID-19 patients with ARDS

Item Type: Thesis (Skripsi)
Additional Information: [No. Panggil: 1810211017] [Pembimbing 1: Hany Yusmaini] [Pembimbing 2: Yanti Harjono Hadiwiardjo] [Penguji: Dhigna Luthfiyani C.P.]
Uncontrolled Keywords: Corticosteroid, COVID-19, ARDS.
Subjects: R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
Divisions: Fakultas Kedokteran > Program Studi Kedokteran (S1)
Depositing User: Soraya Maulidina
Date Deposited: 22 Feb 2022 05:36
Last Modified: 22 Feb 2022 08:04
URI: http://repository.upnvj.ac.id/id/eprint/16420

Actions (login required)

View Item View Item